In this article, we will take a look at 10 Stocks That Could 10X Over the Next 5 Years.

March appears to be finishing on a low note, with the S&P 500 dipping on March 30, pulled down by new rises in oil prices and a sharp decline in technology, as traders moved on from Fed Chair Jerome Powell’s remarks on inflation. The broad-based index fell 0.39%, marking the third consecutive losing session, at 6,343.72. The index’s losses took it slightly over 9% off its closing high, with drops in the technology sector accounting for more than 1% of the decline.

Consumer morale fell about 6% in March, the lowest level since late 2025, due to a volatile mix of rising gas costs and financial sector uncertainty. The Michigan Consumer Sentiment Index dipped 3.7 points to 53.3, falling short of the 55.5 prediction and ending a four-month string of improvements as consumers deal with the aftermath of the Iran conflict.

However, Art Hogan, chief market strategist at B. Riley Wealth Management, believes that the current dip is more likely to be a normal market reset. Speaking about the market scenario, he stated the following:

“There’s a couple of narratives going on, but I think long-term investors should keep in mind that 10% corrections are normal. They happen all the time. On average, every two years we have a 10% correction. It’s also important for investors to understand that the volatility in equities is the price you pay for the higher longer-term returns.”

Market analysts have reached a consensus that the Iranian conflict remains the most significant barrier to expansion. Notably, Morningstar claims that the US equities market is fairly valued at a 12% discount to its intrinsic value and consistently signals a desire to climb higher whenever efforts are made toward a resolution of the ongoing conflict in the Middle East.

Our Methodology

To compile a list of stocks that could 10x over the next 5 years, we researched relevant stocks using multiple financial websites, including EBC Financial, Nasdaq, Yahoo Finance, and Motley Fool. These stocks hold the potential to grow by 1000%, and are also popular among analysts and elite hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10. Pagaya Technologies Ltd. (NASDAQ:PGY)

Pagaya Technologies Ltd. (NASDAQ:PGY) ranks among the stocks that could 10x over the next 5 years. On March 5, Pagaya Technologies Ltd. (NASDAQ:PGY) announced its plan of action at the Morgan Stanley Technology, Media, and Telecom Conference, with CFO Evangelos Perros highlighting the company’s AI-driven lending platform and focus on profitable expansion.

The company strives for $100-$150 million in GAAP net income in 2026, representing around 50% growth, while maintaining positive cash flow amid macroeconomic pressures. Moreover, Perros cited the company’s $1 trillion annual application dataset as a key asset, which drives its underwriting algorithms and gives it a competitive advantage.

At the same time, Pagaya Technologies Ltd. (NASDAQ:PGY) is transitioning from riskier loan generation to partner-led and product-driven development, incorporating AI technology into lending platforms for personal, auto, and point-of-sale financing. It is also expanding into a multi-product platform, including tools like Pre-Screen and Affiliate Optimizer.

Pagaya Technologies Ltd. (NASDAQ:PGY) is a product-focused technology company that deploys data science and proprietary AI-powered technology for financial services and other service providers, their customers, and asset investors in the US, Israel, and the Cayman Islands.

9. Beam Therapeutics Inc. (NASDAQ:BEAM)

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the stocks that could 10x over the next 5 years. On March 3, H.C. Wainwright reaffirmed its Buy rating and $80 price target on Beam Therapeutics Inc. (NASDAQ:BEAM). The rating follows Beam’s fourth-quarter and full-year 2025 results, which showed considerable progress in the company’s product pipeline.

The company announced BEAM-304, an innovative gene editing program for phenylketonuria, with an experimental new medication filing expected in 2026. Meanwhile, new data from BEAM-302 in alpha-1 antitrypsin deficiency continues on schedule for the first quarter of 2026, including information on an FDA-guided prospective accelerated pivotal path.

Beam Therapeutics Inc. (NASDAQ:BEAM) also revealed a $500 million senior secured, long-term non-dilutive contract with Sixth Street, which will serve as support for the possible commercial launch of Risto-Cel. The company reported $1.25 billion in cash, cash equivalents, and marketable securities at the end of 2025. With the expected minimum $200 million pull from Sixth Street, the company forecasts a financial runway through mid-2029.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company developing precision genetic medicines using its proprietary base-editing technology. Its main products include investigational therapies such as BEAM-101 and BEAM-302.